Compare Amphastar Pharmaceuticals Inc (AMPH) vs SoFi Technologies Inc (SOFI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SoFi Technologies (SOFI) trades at $18.78, up 0.86% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $3.61B in 2025, though net income dipped to $481M. The company expanded its ETF lineup with SFYI and acquired AI investing agent Composer, driving positive media coverage. Support sits at $18, resistance at $19.

Outlook: SoFi's bank charter and digital expansion offer growth, but high P/E (41.73) and volatile cash flows pose risks. Analyst consensus target is $22.43 (17% upside), yet mixed ratings reflect execution concerns. Key risks include interest rate sensitivity and competitive fintech pressure.